Page 160 - Read Online

Kumar et al. Cancer Drug Resist 2019;2:161-77 I http://dx.doi.org/10.20517/cdr.2018.27 Page 175

72. Ma G, Ren Y, Wang K, He J. SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci 2011;7:664-72.
73. Yan J, Tsai SY, Tsai MJ. SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin 2006;27:387-94.
74. Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci
2016;17:1-17.
75. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood 2006;108:3646-53.
76. Jalkanen AL, Coleman SJ, Wilusz J. Determinants and implications of mRNA poly (A) tail size-does this protein make my tail look
big? Semin Cell Dev Biol 2014;34:24-32.
77. Liu H, Wu X, Huang J, Peng J, Guo L. miR-7 modulates chemoresistance of small cell lung cancer by repressing MRP 1/ABCC 1. Int J
Exp Pathol 2015;96:240-7.
78. Munoz JL, Rodriguez-Cruz V, Ramkissoon SH, Ligon KL, Greco SJ, et al. Temozolomide resistance in glioblastoma occurs by
miRNA-9-targeted PTCH1, independent of sonic hedgehog level. Oncotarget 2015;6:1190-201.
79. Fang Y, Xu C, Fu Y. MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling. J
Biol Res-Thessalon 2015;22:1-10.
80. Zhu X, Li Y, Xie C, Yin X, Liu Y, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer
2014;135:1286-96.
81. Li H, Zhang P, Sun X, Sun Y, Shi C, et al. MicroRNA-181a regulates epithelial-mesenchymal transition by targeting PTEN in drug-
resistant lung adenocarcinoma cells. Int J Oncol 2015;47:1379-92.
82. De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, et al. MicroRNA-21 links epithelial-to-mesenchymal
transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer
patients. Oncotarget 2015;6:37269-80.
83. Wang Z, Wang N, Liu P, Chen Q, Situ H, et al. MicroRNA-25 regulates chemoresistance-associated autophagy in breast cancer cells, a
process modulated by the natural autophagy inducer isoliquiritigenin. Oncotarget 2014;5:7013-26.
84. Zhang Y, Qu X, Li C, Fan Y, Che X, et al. miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating
Cav-1. Tumor Biol 2015;36:2277-85.
85. Lu L, Ju F, Zhao H, Ma X. MicroRNA-134 modulates resistance to doxorubicin in human breast cancer cells by downregulating
ABCC1. Biotechnol Lett 2015;37:2387-94.
86. Feng R, Dong L. Knockdown of microRNA-127 reverses adriamycin resistance via cell cycle arrest and apoptosis sensitization in
adriamycin-resistant human glioma cells. Int J Clin Exp Pathol 2015;8:6107-16.
87. Wu Q, Yang Z, Xia L, Nie Y, Wu K, et al. Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by
targeting ABC transporters. Oncotarget 2014;5:11552-63.
88. Shang Y, Zhang Z, Liu Z, Feng B, Ren G, et al. miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and
ZNRD1. Oncogene 2014;33:3267-76.
89. To KK, Leung WW, Ng SS. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal
cancer. Exp Cell Res 2015;338:222-31.
90. Li JH, Luo N, Zhong MZ, Xiao ZQ, Wang JX, et al. Inhibition of MicroRNA-196a might reverse cisplatin resistance of A549/DDP
non-small-cell lung cancer cell line. Tumor Biol 2016;37:2387-94.
91. van Jaarsveld MT, van Kuijk PF, Boersma AW, Helleman J, van IWF, et al. miR-634 restores drug sensitivity in resistant ovarian cancer
cells by targeting the Ras-MAPK pathway. Mol Cancer 2015;14:196.
92. Sui H, Cai GX, Pan SF, Deng WL, Wang YW, et al. miR200c attenuates P-gp-mediated MDR and metastasis by targeting JNK2/c-Jun
signaling pathway in colorectal cancer. Mol Cancer Ther 2014;13:3137-51.
93. Shen X, Guo Y, Qi J, Shi W, Wu X, et al. Study on the association between miRNA-202 expression and drug sensitivity in multiple
myeloma cells. Pathol Oncol Res 2016;22:531-9.
94. Zhang AX, Lu FQ, Yang YP, Ren XY, Li ZF, et al. MicroRNA-217 overexpression induces drug resistance and invasion of breast
cancer cells by targeting PTEN signaling. Cell Biol Int 2015;42:1455.
95. Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, et al. A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity
in melphalan-refractory multiple myeloma cells. Clin Cancer Res 2016;22:1222-33.
96. Hiraki M, Nishimura J, Takahashi H, Wu X, Takahashi Y, et al. Concurrent targeting of KRAS and AKT by MiR-4689 is a novel
treatment against mutant KRAS colorectal cancer. Mol Ther Nucleic Acids 2015;4:e231.
97. Zheng HC. The molecular mechanisms of chemoresistance in cancers. Oncotarget 2017;8:59950-64.
98. Ho KK, Myatt SS, Lam EW. Many forks in the path: cycling with FOXO. Oncogene 2008;27:2300-11.
99. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007;7:847-59.
100. Lam EW, Francis RE, Petkovic M. FOXO transcription factors: key regulators of cell fate. Biochem Soc Trans 2006;34:722-6.
101 . Abounader R. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev
Anticancer Ther 2009;9:235-45.
102. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, et al. FoxO3a transcriptional regulation of Bim controls
apoptosis in paclitaxel treated breast cancer cell lines. J Biol Chem 2003;278:49795-805.
103. Sunters A, Madureira PA, Pomeranz KM, Aubert M, Brosens JJ, et al. Paclitaxel-induced nuclear translocation of FOXO3a in breast
cancer cells is mediated by c-Jun NH2-terminal kinase and Akt. Cancer Res 2006;66:212-20.
104. Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, et al. Doxorubicin activates FOXO3a to induce the expression of multidrug
resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther 2008;7:670-8.